4.39
0.11 (2.45%)
| Previous Close | 4.28 |
| Open | 4.30 |
| Volume | 543,125 |
| Avg. Volume (3M) | 1,084,098 |
| Market Cap | 840,598,784 |
| Price / Sales | 55.41 |
| Price / Book | 10.37 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -738.49% |
| Diluted EPS (TTM) | -0.410 |
| Quarterly Revenue Growth (YOY) | 15.10% |
| Total Debt/Equity (MRQ) | 7.07% |
| Current Ratio (MRQ) | 6.01 |
| Operating Cash Flow (TTM) | -58.95 M |
| Levered Free Cash Flow (TTM) | -28.88 M |
| Return on Assets (TTM) | -31.58% |
| Return on Equity (TTM) | -79.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Arbutus Biopharma Corporation | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.5 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.75 |
|
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 21.89% |
| % Held by Institutions | 59.38% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Whitefort Capital Management, Lp | 30 Jun 2025 | 13,343,228 |
| Blackbarn Capital Partners Lp | 30 Jun 2025 | 2,603,521 |
| Foursixthree Capital Lp | 30 Jun 2025 | 2,557,367 |
| 52 Weeks Range | ||
| Median | 5.00 (14.03%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 11 Aug 2025 | 5.00 (14.03%) | Buy | 3.35 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Oct 2025 | Announcement | Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 |
| 06 Aug 2025 | Announcement | Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |